NYSE:ABT
$53.46
(3/19 4:00PM)
-0.6%
| Open | $53.88 |
Mkt Cap | $83.5 Billion |
| High | $53.99 |
52Wk High | $56.79 |
| Low | $53.19 |
52Wk Low | $41.27 |
| Volume | 16.3 Million |
Avg Vol 10D | 8.3 Million |
ABT Revenue
For a long time, value investors have used the current share price relative to sales per share levels as an important valuation tool. We utilize a historical weighted average methodology that treats recent years more importantly in the calculation. When looking at ABT through this framework, we can see that our weighted average historical high and low Price to Sales per share ratios over the last 10 years are 4.05x and 3.02x respectively.
Utilizing this range we can see that ABT’s current Price to Sales per share ratio of 2.75x is significantly below its average levels historically. In fact, with a current price of $54.52, ABT is a full 23% below its average Price to Sales ratio at comparable sales levels. This is a rare occurrence and, when taken in context of the other areas of our analysis, can be a strong positive for our outlook for ABT.
ABT Cash Earnings
Looking at ABT specifically in their Cash Earnings capabilities, Ockham views ABT as significantly below its historical average multiple of cash earnings as calculated by Ockham. Similar to our analysis of sales per share, Ockham looks at the last 10 years of cash earnings levels for ABT to identify where the current high and low price levels have been historically in relation to profit per share. Again, we utilize a weighted average methodology which relies more heavily on recent years of data. This weighted average framework provides us with an average high Price to Cash Earnings ratio per share of 19.54 and a 14.63 low over the same period.
Now that ABT’s current price is $54.52 and its Price to Cash Earnings ratio is 10.80, we are very positive on its outlook from the cash earnings perspective. In fact, ABT is now trading a full 37% below its average historical Price to Cash Earnings ratio at these profit per share levels. When our clients ask us why ABT has great long term potential, the Cash Earnings levels to current stock is one of our primary reasons. But naturally, now we need for the overall market to recognize this disparity.
ABT Dividends
A positive Ockham rating does not require a company to pay out an inviting dividend or a dividend at all. However, we believe dividends provide a useful measure of a company's inherent expectations.
Comparable to our analysis of Sales and Cash Earnings per share, we examine dividend yields from ABT against the historic high and low levels over an available data range. Because ABT has an established history of paying a dividend to shareholders, there is value in comparing recent dividends to historical dividends. In ABT’s case, the estimated annual dividend is $1.76 producing a current dividend yield of 3.23%. The highest dividend yield from ABT in recent history was 4.26% while the lowest dividend yield was 1.53%. A current dividend yield of 11.57% above the historical median is favorable in our analysis of ABT.
First ABT News on Fox Business in More Than a Month
There has not been much to report from ABT in the last few weeks at least, but Fox Business talked about the stock recently.
Premium Content - please sign up for Ockham PREMIUM to gain full access and to see what Fox Business said about ABBOTT LABORATORIES
Learn About RazorWire?ABT's Back in the News After More than a Month on The Opening Bell on Fox Business
It's been at least a month since we noticed any major news coverage of ABT, so the story in The Opening Bell on Fox Business may get the ball rolling.
Based on our methodology, Abbott Laboratories should hold some appeal to value investors as we view it as Undervalued. Crowd sentiment is leaning to the bearish side, according to the robust data set collected by the Motley Fool CAPS survey. We noticed recently that in comparison to all other stocks we analyze in the news; ABT has received less coverage from the financial media in business television and blogs.
“… Be used in routine clinical practice, it's inferior in terms of the researchers comparing it to ABBOTT LABORATORIES, comparable product. The stock take ago hit. …”
Abbott Laboratories (ABT) Discussed on CNBC's Squawk Box
Abbott Laboratories is in the news. Find out how this impacts ABT trading on Ockham Research.
Trying to avoid for the last very good news for them. Also news coming in europe from belgium, the chemical and pharmaceutical company. You mentioned this a couple minutes ago is confirming that they are selling their drug-making activities to the u.S. Rival ABBOTT LABORATORIES for 4.5 billion euros. Solvay investors in belgium were not happy with this news today, the share's trading almost 2% down at the moment. Of course, ABBOTT LABORATORIES is very interested in solvay's vaccine activities. Now we are going to singapore with adam. >> thank you very much, >>> japan led the markets down today as we saw, the eight-month highs versus the u.S. Dollar. The finance minister's comments saying he didn't think the movements were normal, but they continued to watch what happens with the japanese yen versus the u.S. Dollar. And rose to about 88 plus versus the u.S. Dollar. Particularly the autos and the consumer electronics. Many of these companies have budgets between 90 and 95, and for every one yen movement versus the u.S. Dollar against of course, this is a negative for their overall operating profits. Meanwhile, we also saw a bleak picture for the financial stocks on more prospects that, of course, financials will have to raise more money to boost their
“… val ABBOTT LABORATORIES for 4.5 billion euros. Solvay investors in belgium were not happy with this news today, the share's trading almost 2% down at the moment. Of course, ABBOTT LABORATORIES is very interested in solvay's vaccine activities. Now we are going to singapore with adam. >> thank you very much, >>> japan led the markets down today as we saw, the eight-month highs versus the u.S. Dollar. The finance minister's comments saying he didn't think the movements were normal, but they continued to watch what happens with the japanese yen versus the u.S. Dollar. And rose to about 88 plus versus the u.S. Dollar. Particularly the autos and the consumer electronics. Many of these companies have budgets between 90 and 95, and for every one yen movement versus the u.S. Dollar against of course, this is a negative for their overall operating profits. Meanwhile, we also saw a bleak picture for the financial stocks on more prospects that, of course, financials will have to raise more money to boost their …”
Abbott Laboratories (ABT) Discussed on Fox Business's Fox Business
Abbott Laboratories is in the news. Find out how this impacts ABT trading on Ockham Research.
Global industries, that blue chips, that run down as much as the rest of the market and great quality companies, trading at the same price as crummy companies, and an example would be abbott labs, abt, a medical products company that has diagnostics, medical devices, and stents, a bestseller, bioengineered product, humera,
“… cal devices, and stents, a bestseller, bioengineered product, humera, …”
Abbott Laboratories (ABT) Discussed on CNBC's Fast Money
Abbott Laboratories is in the news. Find out how this impacts ABT trading on Ockham Research.
But abbott, what did did today. Their major drugs don't come off of patent until 2017. Lipitor and pfizer comes off abbott sets up nicely on value yags on a lot of different I still like abt. >> and petey, on those potential targets that you named, do you like buying outside calls on some of those targets as a gamble >> you do? >> activity all of the time, and one name that gets interesting.
“… like buying outside calls on some of those targets as a gamble >> you do? >> activity all of the time, and one name that gets interesting. …”
Abbott Laboratories (ABT) Discussed on Fox Business's America's Nightly Scoreboard
Abbott Laboratories is in the news. Find out how this impacts ABT trading on Ockham Research.
Two of the premiere business people in california coming up live here on "scoreboard". And we want to know what you indid on madoff or what they didn't do on madoff. Didn't do on madoff. Abt on stanford? Sell or a text your message to 369249.
“… Two of the premiere business people in california coming up live here on "scoreboard". And we want to know what you indid on madoff or what they didn't do on madoff. Didn't do on madoff. Abt on stanford? Sell or a text your message to 369249. …”
Abbott Laboratories (ABT) Discussed on CNBC's Street Signs
Abbott Laboratories is in the news. Find out how this impacts ABT trading on Ockham Research.
40% in 2008, the medallion fund and on average 30% per year since inception. >> which stocks is medallion >> one of their largest new positions is ABBOTT LABORATORIES, abt, the company trades for 13 times forward earnings, and in terms of safety, this company raises dividends every year for 25 years in a row. I think it's a great plan and
“… pany raises dividends every year for 25 years in a row. I think it's a great plan and …”
Abbott Laboratories (ABT) Discussed on CNBC's Closing Bell
Abbott Laboratories is in the news. Find out how this impacts ABT trading on Ockham Research.
Has been in the witness protection program for a number he has put a lot of guys away in jail. He helped convict nicholas gaginiani a couple years ago. He's a major inform abt and what he is telling federal authorities, nick cosmo, he and another associate was one of the guys who attempted to collect money on behalf of the genovese,
“… e was one of the guys who attempted to collect money on behalf of the genovese, …”